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The human apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3G (APOBEC3G, or hA3G) protein, provides cells with
an intracellular antiretroviral activity that is associated with the hypermutation of viral DNA through cytidine deamination. Indeed, hA3G
belongs to a family of vertebrate proteins that contain one or two copies of a signature sequence motif unique to cytidine deaminases
(CTDAs). We have constructed secondary structure models of the APOBEC proteins through a combination of structure prediction and
subsequent alignment with nucleotide CTDAs whose structures have been solved to high resolution. Secondary structure elements common
to all CTDAs are predicted, in addition to structural features that are apparently unique to the APOBEC family of proteins. Most notably, a
putative looped-out helix abuts an amino acid that modulates the susceptibility of A3G proteins to the antagonistic action of the human and
simian immunodeficiency virus (HIV and SIV) Vif proteins. Using the structure models as a guide, we reflect on mutagenesis studies of the
APOBEC1 (A1), hA3G and activation induced deaminase (AID) proteins, with emphasis on the determinants of cytidine deamination and
antiviral activities.
D 2005 Elsevier Inc. All rights reserved.
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In recent years, a novel intracellular defence mechanism
against retroviral infection has been identified. This disco-
very provided an explanation for the observation that the HIV
Vif (viral infectivity factor) protein is required for viral
replication in certain cell types, termed non-permissive (e.g.,
primary CD4 T lymphocytes), but not in others, termed
permissive. In particular, non-permissive cells were found to
express a protein, hA3G (formerly called CEM15), that
potently suppresses the infectivity and replication of vif-
deficient HIV (Sheehy et al., 2002). The presence of hA3G in
virus-producing cells results in its incorporation into virions,
and in cytidine (C) to uridine (U) deamination of mostly
minus strand (or first strand) reverse transcripts: such
mutations register as guanosine (G) to adenosine (A) tran-0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.01.038
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E-mail address: michael.malim@kcl.ac.uk (M.H. Malim).sitions in plus stranded DNA (Harris et al., 2003; Lecossier
et al., 2003; Mangeat et al., 2003; Zhang et al., 2003).
Because mutational (or editing) frequencies can exceed 10%
of all G residues, this phenomenon is termed hypermutation.
In addition to the inactivation of viral genetic elements
through hypermutation, reduced accumulation of viral
cDNAs has been noted for Dvif infections carried out in
the presence of hA3G (Mangeat et al., 2003; Simon and
Malim, 1996). The Vif protein prevents this mutational on-
slaught by binding to hA3G and recruiting a ubiquitin ligase
such that hA3G is degraded by the proteasome and excluded
from budding virions (Conticello et al., 2003; Mariani et al.,
2003; Marin et al., 2003; Mehle et al., 2004; Sheehy et al.,
2003; Stopak et al., 2003; Yu et al., 2003, 2004b).
The antiviral activity of hA3G extends well beyond HIV
and, to date, has been shown to target a variety of substrates
including other retroviruses such as various SIVs, equine
infectious anaemia virus (EAIV) and murine leukaemia
virus (MLV) (Gaddis et al., 2004; Harris et al., 2003;05) 147–153
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hepadnavirus HBV (Rosler et al., 2004; Turelli et al., 2004).
The hA3G gene is located on chromosome 22, where it is
flanked by genes coding for highly related proteins named
APOBEC3A through H (Harris and Liddament, 2004;
Jarmuz et al., 2002). Of these, APOBEC3F (hA3F) and
APOBEC3B (hA3B) also possess antiviral activity against
HIV (Bishop et al., 2004a; Liddament et al., 2004; Wiegand
et al., 2004; Zheng et al., 2004), whereas hA3B and
APOBEC3C (hA3C) can inhibit certain SIV isolates (Yu et
al., 2004a). Two rodent family members, mouse APOBEC3
(mA3) and rat APOBEC1 (rA1), also possess potent anti-
HIV activity when expressed in human cells (Bishop et al.,
2004a, 2004b; Mariani et al., 2003). Perhaps somewhat
surprisingly, mA3 does not inhibit infection by the murine
retrovirus, MLV (Bishop et al., 2004a).
The APOBEC3 proteins belong to a family of polynucleo-
tide CTDAs that further includes APOBEC1 (A1), APO-
BEC2 (A2) and activation induced deaminase (AID)
(Conticello et al., 2005; Harris and Liddament, 2004; Jarmuz
et al., 2002). A1, the founder member, is expressed in human
gastrointestinal tissues and specifically edits C6666 in
apolipoprotein B mRNA to generate a premature stop codon
(Teng et al., 1993). AID is expressed in B cells and is essential
for both somatic hypermutation and class switch recombina-
tion during antibody gene diversification; most groups
consider both processes to be initiated through C-to-U editing
of DNA at the immunoglobulin loci (Lee et al., 2004). A2 is
expressed most prominently in cardiac and skeletal muscle
(Liao et al., 1999), but its function is currently unknown.Structures of nucleotide CTDAs
All members of the APOBEC protein family contain one
or two copies of a His/Cys-X-Glu-X23–28-Pro-Cys-X2-CysFig. 1. Structures of the cytidine deaminase catalytic domain. (A) Nucleotide CT
which supports the proper positioning of the a-helices that contain the catalytic an
contain an insert that is predicted to fold into an a-helical structure, a3. In A3G, th
interaction with Vif. a-Helices are shown in yellow and h-strands in pink. (For i
referred to the web version of this article.)signature motif that is characteristic of CTDAs. In the case
of A1, there is good agreement that disruption of the highly
conserved residues abolishes both nucleic acid binding and
RNA editing (MacGinnitie et al., 1995; Navaratnam et al.,
1995; Teng et al., 1999; Yamanaka et al., 1994), and
mutation of the Glu residue has been shown to abolish the
DNA mutator activity of AID (Ramiro et al., 2003).
Crystal structures for nucleotide CTDAs from Escher-
ichia coli (Betts et al., 1994), Bacillus subtilis (Johansson et
al., 2002), Saccharomyces cerevisiae (Xie et al., 2004) and
most recently humans (Chung et al., 2005) are available.
These structures reveal a core h1h2a1h3a2h4h5 arrangement
in which the five h-strands form a mixed sheet that supports
the parallel positioning of two a-helices that contain the His,
Cys and Glu residues that are required for zinc-coordination,
proton transfer and catalysis (Fig. 1A) (Wedekind et al.,
2003). The availability of this information together with the
sequences of more than ten APOBEC proteins offers an
opportunity to perform homology modeling. Since no
APOBEC protein structure has yet been determined, such
analyses may provide clues as to common trends and
differences among the organizations of APOBEC family
members. Structural insight into the APOBEC proteins is of
considerable interest not only from the perspective of basic
biological understanding, but also for future rational drug
design efforts.
Homology structure models based on E. coli or yeast
nucleotide CTDAs have previously been proposed for A1,
AID and hA3G (Navaratnam et al., 1998; Schrofelbauer et
al., 2004; Ta et al., 2003; Wedekind et al., 2003; Xie et al.,
2004; Zaim and Kierzek, 2003). In general, these models
were derived by alignment of the His/Cys-X-Glu-X23–28-
Pro-Cys-X2-Cys motif and subsequent fitting of the
APOBEC amino acid sequence onto the CTDA structure.
Intriguingly, these models show little similarity outside of
the catalytic core, which may be due to different consid-DAs show a consensus h1h2a1h3a2h4h5 motif that forms a mixed h-sheet
d zinc-coordinating residues. (B) Between h4 and h5, APOBEC proteins all
is helix is adjacent to residue 128 that is associated with the species-specific
nterpretation of the references to colour in this figure legend, the reader is
Minireview 149erations being applied at the fitting step of the modeling.
Because there are considerable differences in the lengths
and sequences of the APOBEC and nucleotide CTDA
proteins, alignment of the sequences is, indeed, all but
straightforward.Computer-assisted structure predictions
As an alternative approach to APOBEC protein struc-
ture prediction, we performed computer-assisted secondary
structure predictions using the SAM-T02 package, which
predicts elements of protein structure from the amino acid
sequence (Karchin et al., 2003; Karplus et al., 2001,
2003). In contrast to the predictions noted above, this
analysis avoids the ambiguity of how to fit the APOBEC
polypeptides onto the backbone of CTDA structures. For
all our analyses, we limited the predictions to a-helices
and h-strands. As an initial validation of this approach,
we analyzed the four nucleotide CTDA sequences for
which structures are known; close agreement between
predicted and actual a-helices and h-strands was found in
all cases. Except for one 2-residue h-strand (E. coli) and
one 4-residue a-helix (B. subtilis), all structural elements
were correctly identified. The overall accuracy of pre-
diction was 72% for any given residue, with most of the
error being caused by modest overestimations in the
length of a-helices or h-strands. The process was then
repeated for a total of 17 APOBEC proteins, and some of
the results are depicted in Fig. 2, where predicted a-
helices and h-strands of the APOBEC proteins are aligned
with crystallography-derived secondary structures of
nucleotide CTDA enzymes by a combination of sequence
and structural similarity. This approach immediately
revealed the prediction of a1, h3, a2 and h4 throughout
the APOBEC family of proteins. This was not unexpected
since this region harbors the catalytic core and therefore
suggests that this central part of the CTDA fold is
structurally well conserved between nucleotide and poly-
nucleotide CTDAs.The amino-terminus
The identification of candidates for h1, h2 and h5 proved
less obvious among the APOBEC proteins. The N-terminal
regions preceding a1 showed a strong prediction for one h-
strand flanked by two weaker predicted h-strands. In the h-
sheet of the CTDA fold, h1 is centrally located between h2
and h3, and h2 provides a turn at the edge of the structure
(Fig. 1A). Reasoning that h1 may be more constrained due
to its central position in the CTDA fold, we assigned the
second and third h-strands to correspond with h1 and h2,
respectively. We note that this assignment is tentative only
and that the extent of the predicted h2 strand is limited. One
particularly complicating factor is the prediction of an a-helix for A1 at the presumed position of h1. Because
structure prediction is more accurate when shorter amino
acid sequences are analyzed, we next repeated the procedure
using a series of truncated A1 sequences from human, rat
and mouse. Two h-strands that may correspond to h1 and h2
were predicted, when these shortened sequences were
analyzed (Fig. 3).APOBEC CTDA domains contain an additional a-helix
Perhaps the most striking difference between the
predicted secondary structures of APOBEC proteins and
the established structures of nucleotide CTDA proteins
occurs C-terminal to h4. Whereas the nucleotide CTDA h4
is followed by a turn and then h5 the APOBEC proteins
are predicted to have an intervening a-helix. Since the h5-
strands of the APOBEC proteins share sequence similarity
with the h5 regions of the nucleotide CTDA molecules
(Fig. 2), we propose that the APOBEC proteins have
acquired an insert between h4 and h5 that may take the
form of a looped-out helix (Fig. 1B). We have encoun-
tered this feature in all known APOBEC proteins (not
shown), suggesting that it may be a defining element of
the family.
Of particular interest is the fact that a critical amino acid
residue in A3G proteins that constrains species-specific
interactions with Vif has been mapped to this region. SIVs
and HIVs encode divergent Vif proteins that induce the
proteolytic degradation of cognate simian or human A3G
proteins through the recruitment of cellular ubiquitin ligase
complexes (Liu et al., 2004; Yu et al., 2003). A single amino
acid difference at position 128 – aspartic acid in human versus
lysine in African green monkey (AGM) A3G (Fig. 2) –
confers susceptibility to HIV or SIVagm Vif, respectively
(Bogerd et al., 2004; Mangeat et al., 2004; Schrofelbauer et
al., 2004; Xu et al., 2004).We infer that the positioning of this
residue adjacent to an exposed a-helix renders it ideal for
participating in the direct interaction with Vif (or other
unknown regulatory factors).The two CTDA domains of hA3G
Based on the points summarized above, we predict that
the CTDA fold of APOBEC proteins conform to a h1h2a1
h3a2h4a3h5 arrangement rather than the h1h2a1h3a2h4h5
arrangement seen in the nucleotide CTDA enzymes (Fig. 1).
We emphasize, however, that while this model is a useful
starting point for assigning potential activities or attributes
to regions of APOBEC proteins (discussed further below), it
leaves much to be explained in terms of the specific
functions of APOBEC CTDA domains, and the differences
between domains.
hA3B, hA3F and hA3G all have two CTDA domains that
could contribute differentially to substrate recognition (e.g.,
Fig. 2. Alignment of predicted APOBEC protein structures with crystallography derived structures of cytidine deaminases. Predicted APOBEC protein
structures: human activation induced deaminase (AID), human APOBEC1 (A1), human APOBEC2 (A2) and human APOBEC3G (A3G). As hA3G has a
duplicated primary structure, the sequence has been divided into N- and C-terminal domains (A3G-N and A3G-C, respectively), although the prediction was
performed with the entire amino acid sequence. Predictions of the APOBEC structures were generated using the SAM-T02 package. Four different outputs
were generated for each sequence; a given residue was only assigned to an a-helix or h-strand when it was predicted in three out of four cases. Crystallography
derived secondary structures (Kabsch and Sander, 1983) of nucleotide CTDAs are from human, Saccharomyces cerevisiae (yeast), Bacillus subtilis and
Escherichia coli. Crystallographic data derived from cytosine deaminases were not included as these enzymes have significantly different structures. a-Helices
are shown in yellow and h-strands in pink. Catalytic residues are indicated in bold and the 128 residue in hA3G that governs the species-specific interaction
with Vif is boxed. Structural elements of the E. coli pseudocatalytic domain are indicated with an asterisk. In addition to the sequences shown, the following
APOBEC proteins were also analyzed in the same way: chicken and zebrafish AID; rat, mouse, rabbit and hamster A1; rat and mouse A2; human A3 A, B, C
and F; African green monkey A3G. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Minireview150RNA versus DNA) and target site sequence preferences.
Based on structure predictions and the conservation of the
His/Cys-X-Glu-X23–28-Pro-Cys-X2-Cys motif (Fig. 2), itmight have been predicted that each domain would mediate
cytidine deamination during retrovirus infection. This issue
has recently been addressed by substituting the conserved
Fig. 3. Structure prediction with truncated APOBEC1 sequences from human, rat and mouse. Structure predictions were performed on sequences as they are
shown. Although an a-helix is predicted in this region when the whole amino acid sequences are used, analysis of truncated sequences permits prediction of h-
strands. a-Helices are shown in yellow and h-strands in pink. (For interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
Minireview 151His, Cys or Glu residues in either the N- or C-terminal
CTDA domains or both of hA3G (Newman et al., 2005).
Unexpectedly, whereas only one of the domains needs to be
intact to achieve anti-HIVactivity in a tissue culture model of
infection, with no preference as to which one, an intact C-
terminal CTDA domain is essential for cytidine deamination.
Thus, the two CTDA domains of hA3G are not equivalent to
each other, with only the C-terminal domain appearing to be
catalytically active. This indicates that viral DNA editing is
not always required for the antiviral activity of hA3G. These
findings are also in keeping with an hA3G-mediated antiviral
activity against HBV that does not require cytidine
deamination (Rosler et al., 2004; Turelli et al., 2004), and
indicate that APOBEC proteins can confer anti-viral
phenotypes by a mechanism distinct from hypermutation.
Interestingly, this separation of activities is somewhat
reminiscent of the segregation of somatic hypermutation
from class switch recombination seen for certain mutant
forms of AID (Barreto et al., 2003; Shinkura et al., 2004; Ta
et al., 2003).The pseudocatalytic domain
Our alignment additionally highlights the structural
divergence of the E. coli CTDA from other nucleotide
CTDAs. This enzyme is active as a dimer and the C-
terminal sequence is structurally similar to the CTDA fold
but lacks the catalytic residues. Accordingly, this region has
been termed the pseudocatalytic domain and it provides the
dimeric E. coli protein with a quaternary structure that is
equivalent to the tetrameric organization of the B. subtilis, S.
cerevisiae and human CTDAs (Johansson et al., 2002).
Based on our analysis, none of the APOBEC proteins
appear to contain a domain that is equivalent to the
pseudocatalytic domain, suggesting that the E. coli CTDA
is an unsuitable template for inferring the structural
organization of APOBEC proteins. There is some evidence
to suggest that hA3B, hA3F and hA3G form homo- and
heterodimers (Jarmuz et al., 2002; Shindo et al., 2003;
Wiegand et al., 2004). However, since these proteins have a
duplicated CTDA domain, one would expect the assem-
bled dimers to actually resemble the tetrameric structure
with four active sites and four coordinated zinc ions. Thisfurthermore suggests that APOBEC proteins with single
CTDA domains will assemble into tetramers.Carboxy-terminal leucine-rich regions
The APOBEC proteins show an organization of their
C-terminal sequences that is distinctly different from the
pseudocatalytic domain of the E. coli CTDA. Specifically,
these regions are leucine-rich and are predicted to contain
significant amounts of a-helix (Fig. 2). These features are
commonly found in protein domains involved in protein–
protein interactions, and there is evidence to support that
this is the case with A1 and AID. First, mutations and
deletions within the C-terminal domain of A1 do not affect
deamination activity but do compromise multimerization,
co-factor binding and nuclear distribution (MacGinnitie
et al., 1995; Teng et al., 1999; Yamanaka et al., 1994;
Yang et al., 1997, 2001). Second, C-terminal mutations in
AID can yield proteins that remain competent for trigger-
ing somatic hypermutation but are defective for class-
switch recombination and normal nuclear distribution
(Barreto et al., 2003; Bransteitter et al., 2004; Brar et al.,
2004; Ito et al., 2004; Shinkura et al., 2004; Ta et al.,
2003). In both cases, protein–protein interactions have
been implied, either directly or indirectly, to account for
these effects. Importantly, these studies demonstrate func-
tional segregation of APOBEC C-terminal domains from
elements essential for deamination activity: this is con-
sistent with our current prediction that this region is not
part of the CTDA motif.Summary
We have presented structure models for APOBEC
proteins that were generated by computational prediction
and subsequent alignment with known CTDA structures.
Interestingly, most structural elements common to CTDAs
were readily identified in APOBEC proteins. One appa-
rently unique feature of the APOBEC proteins is the
presence of a predicted a-helix between two h-strands of
the canonical CTDA fold. Since the species-specific
interaction of Vif with A3G proteins is dependent on this
Minireview152region, we propose that this element has the potential to
serve as a binding site for co-factors that may modulate
APOBEC protein function. The C-terminal sequences of
APOBEC proteins also contain a-helices that appear
structurally distinct from the core CTDA domain and
may be optimally suited for protein–protein interactions.
Indeed, disruptions in this region are known to interfere
selectively with the class switch recombination function of
AID, but not with the induction of somatic hypermutation.
By analogy, it will be interesting to see how helical
regions C-terminal to the conserved CTDA folds of hA3G
may participate in biological activity, particularly with
respect to the editing-independent antiviral activity.References
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